Clinical Oncology Next Generation Sequencing (NGS) Market Report 2019-2029

臨床腫瘍学次世代シーケンス(NGS)の世界市場2019-2029

◆タイトル:Clinical Oncology Next Generation Sequencing (NGS) Market Report 2019-2029
◆商品コード:VGN910394
◆調査・発行会社:visiongain
◆発行日:2019年8月23日
◆ページ数:167
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Sigle UserGBP3,499 ⇒換算¥468,866見積依頼/購入/質問フォーム
Departmental/Five UserGBP3,899 ⇒換算¥522,466見積依頼/購入/質問フォーム
Site LicenseGBP4,999 ⇒換算¥669,866見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"臨床腫瘍学次世代シーケンス(NGS)の世界市場2019-2029"について調査・分析しなどの情報をお届けいたします。

Clinical Oncology Next Generation Sequencing (NGS) – our new study reveals trends, R&D progress, and predicted revenuesWhere is the Clinical Oncology Next Generation Sequencing (NGS) market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2029, assessing data, trends, opportunities and business prospects there.
Discover how to stay ahead
Our 242-page report provides 35 tables, 190 charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Clinical Oncology Next Generation Sequencing (NGS) market. See how to exploit the opportunities.
Forecasts to 2029 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2029, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), Component profiles and commercial developments.
Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, there are 4 segmentations of the Clinical Oncology Next Generation Sequencing (NGS) market, with forecasts for 4 Components, 8 Technologies, 6 Applications and 4 End Users, each forecasted at a global and regional level.
Global Clinical Oncology Next Generation Sequencing (NGS) Market by Component
• Sequencing Platform
• Sequencing Products
• End Users and Reagents
• Services
Global Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
• Microarray
• Ion Semiconductor Sequencing
• Pyro-Sequencing
• Synthesis Sequencing (SBS)
• Real Time Sequencing (SMRT)
• Ligation Sequencing
• Reversible Dye Termination Sequencing
• Nano -Pore Sequencing
• Others
Global Clinical Oncology Next Generation Sequencing (NGS) Market by Application
• Whole Tumor Genome Sequencing
• Whole Tumor Exome Sequencing
• Targeted Tumor Genome Profiling
• Tumor Transcriptome Sequencing
• Tumor -normal Comparisons
• Others
Global Clinical Oncology Next Generation Sequencing (NGS) Market by End User
• Hospital Laboratories
• Clinical Research Organizations
• Diagnostic Laboratories
• Others
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 7 regional and 17 leading national markets:
• North America:
• US
• Canada
• Latin America:
• Brazil
• Mexico
• Rest of Latin America
• Western Europe:
• Germany
• The UK
• Italy
• France
• Spain
• Nordic
• Benelux
• Rest of Western Europe
• Eastern Europe:
• Russia
• Poland
• Rest of Eastern Europe
• Asia-Pacific:
• Japan
• China
• India
• Australia & New Zealand
• ASEAN
• Rest of Asia-Pacific
• MEA:
• GCC Countries
• South Africa
• Northern Africa
• Rest of MEA
The report also includes profiles and for some of the leading companies in the Clinical Oncology Next Generation Sequencing (NGS) market, with a focus on this segment of these companies’ operations.
There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, Russia, Germany and China in particular, will continue to achieve high revenue growth to 2029.
Leading companies and the potential for market growth
Overall world revenue for Clinical Oncology Next Generation Sequencing (NGS) will surpass $3.87 billion in 2019, our work calculates. We predict strong revenue growth through to 2029.
Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Clinical Oncology Next Generation Sequencing (NGS) Market report helps you
In summary, our 253-page report provides you with the following knowledge:
• Revenue forecasts to 2029 for 4 segmentations of the Clinical Oncology Next Generation Sequencing (NGS) market, with forecasts for 4 Components, 8 Technologies, 6 Applications and 4 End Users, each forecasted at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2029 for 6 regional and 21 key national markets – See forecasts for the Clinical Oncology Next Generation Sequencing (NGS) market in North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, the UK, Italy, France, Nordic Countries, Benelux, China, India, Japan, Australia & New Zealand, ASEAN countries, GCC Countries, South Africa and Northern Africa.
• Stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market – including company profiles for 10 of the major companies involved in the Clinical Oncology Next Generation Sequencing (NGS) market
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.
Visiongain’s study is for everybody needing commercial analyses for the Clinical Oncology Next Generation Sequencing (NGS) Sequencing market and leading companies. You will find data, trends and predictions.
Get our report today The Clinical Oncology Next Generation Sequencing (NGS) Market Forecast 2019-2029: Revenue Prospects by Component (Sequencing platform, Sequencing products, End users and Reagents, Services), by Technology (Ion Semiconductor Sequencing, Pyro-Sequencing, Synthesis Sequencing (SBS), Real Time Sequencing (SMRT), Ligation Sequencing, Reversible Dye Termination Sequencing, Nano -Pore Sequencing, Others), by Application (Whole Tumor Genome Sequencing, Whole Tumor Exome Sequencing, Targeted Tumor Genome Profiling, Tumor Transcriptome Sequencing, Tumor -normal Comparisons, Others), by End user (Hospital Laboratories, Clinical Research Organizations, Diagnostic Laboratories, Others) and Geography.

【レポートの目次】



★調査レポート[臨床腫瘍学次世代シーケンス(NGS)の世界市場2019-2029] ( Clinical Oncology Next Generation Sequencing (NGS) Market Report 2019-2029 / VGN910394) 販売に関する免責事項
[臨床腫瘍学次世代シーケンス(NGS)の世界市場2019-2029] ( Clinical Oncology Next Generation Sequencing (NGS) Market Report 2019-2029 / VGN910394) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆